癌症治疗中免疫相关不良事件文献可视化分析

Visualization Analysis of Literature on Immune-Related Adverse Events in Cancer Therapy

目的为免疫检查点抑制剂(ICI)用于癌症治疗中免疫相关不良事件(irAEs)的进一步研究提供参考。方法计算机检索Web of Science数据库,检索时限为自建库起至2023年2月1日。运用Excel 2016版和VOSviewer 1.6.18版软件,对纳入文献的发表年份、发表期刊、作者及研究机构、文献共被引及关键词共现等进行文献计量学分析。结果共纳入2735篇文献,始发于2012年,2015年后发文量和引用频次呈逐年递增趋势。发文量最大的国家及研究机构分别是美国(1058篇,38.68%)及美国德克萨斯大学MD安德森癌症中心(137篇,5.01%);发文量最大、文献被引频次最高的作者分别为JOHNSON(32篇,1.17%),POSTOW(3144次),期刊均为Journal for Immuno Therapy of Cancer(117篇、4.28%,4720次);27篇高被引(被引频次≥200次)文献聚焦于纳武利尤单抗、帕博利珠单抗和伊匹木单抗等在黑色素瘤、肾癌及肺癌等实体瘤中的免疫治疗研究,以及ICI的irAEs的特征与预后、毒性管理指南、系统综述与荟萃分析等研究;关键词可聚为4类,主要包括免疫治疗、癌症、双盲临床试验、安全性等主题。结论采用文献计量学方法可清晰、直观地了解全球ICI用于癌症免疫治疗中irAEs的研究现状及热点。

Objective To provide a reference for further research on the immune-related adverse events(irAEs)in cancer therapy by immune checkpoint inhibitors(ICIs).Methods Relevant literature in the Web of Science database from the inception to February 1,2023 was searched.Bibliometric analysis was performed on the publication year,journal,author,research institution,co-citation and keyword co-occurrence of the included literature by the Excel 2016 and VOSviewer 1.6.18 softwares.Results A total of 2735 literature was included,the first one was published in 2012,the quantity of publications and citation frequency showed an increasing trend year by year after 2015.The United States and the University of Texas MD Anderson Cancer Center was the country and research institution with the largest quantity of publications,publishing 1058 literature(38.68%)and 137 literature(5.01%)respectively.JOHNSON was the author with the largest quantity of publications(32 literature,1.17%),and POSTOW was the author with the highest citation frequency of literature(3144 times).The Journal for Immuno Therapy of Cancer was the journal with the largest quantity of publications(117 literature,4.28%)and the highest citation frequency of literature(4720 times).Twenty-seven literature with high citation(frequency≥200 times)focused on the immunotherapy research of nivolumab,pembrolizumab and ipilimumab in solid tumors such as melanoma,kidney cancer and lung cancer,as well as the characteristics and prognosis,toxicity management guidelines,systematic reviews and Meta-analyses of irAEs of ICIs.Keywords could be grouped into four categories,mainly including these topics such as immunotherapy,cancer,double-blind clinical trials and safety.Conclusion Bibliometric study can provide a clear and intuitive understanding of the current research status and hot spots of irAEs in cancer immunotherapy by ICIs in the world.